Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the fourth quarter and year ended December 31, 2012.
Revenue for the fourth quarter of 2012 was approximately $1.0 million, compared to approximately $896,000 in the fourth quarter of 2011. Revenue for all of 2012 was approximately $3.3 million, compared to approximately $3.6 million for 2011. Fluctuations in revenue were due primarily to the timing of receivables. Revenue from the sale of demonstration LuViva® Advanced Cervical Scan devices, for the year ended December 31, 2012, was approximately $72,000.
The net loss attributable to common stockholders for the fourth quarter of 2012 was approximately $1.2 million, or $0.02 per share. This compares to a net loss attributable to common stockholders of approximately $2.8 million, or $0.05 per share, in the comparable quarter of 2011. The net loss attributable to common stockholders for 2012 was approximately $4.4 million, or $0.08 per share, compared to a net loss attributable to common stockholders of approximately $6.6 million, or $0.14 per share, for 2011.
Cash on hand at December 31, 2012, was approximately $1.0 million, as compared to approximately $2.2 million at December 31, 2011. Since January 1, 2013, approximately $1.65 million has been raised from warrant exercises. While additional funding is being sought to support manufacturing and marketing activities, management believes that its anticipated future sales, as well as other funds from partnerships and grants, should be sufficient to support existing operations through the second quarter of 2013.“We are very pleased to be shipping eight additional LuViva devices and disposable Cervical Guides in the first quarter to our Canadian partner and are completing assembly of our first Edition 3 CE Marked units, which we anticipate shipping to Europe in the second quarter,” said Mark L. Faupel, Ph.D., Chief Executive Officer and President of Guided Therapeutics.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV